MED-C Expands its Board of Directors

    OWASSO, OK, February 24, 2016 /24-7PressRelease/ -- Jeff Allen, Chairman of The Molecular Evidence Development Consortium (MED-C) and Executive Director of Friends of Cancer Research, is pleased to announce the addition of Mr. Ron Collette, CISSP to our existing board of directors, the members of which also include:

- Brian Druker (Head of Knight Cancer Center at Oregon Health Science University)
- Mark McClellan (Director of the Duke-Robert J. Margolis MD, Center for Health Policy)
- George Rehm (Managing Partner at Aeris Capital)
- Marc Samuels (CEO of ADVI, a Washington, DC-based lifescience and healthcare services consulting firm)
- Sean Tunis (Chief Executive Officer of the Center for Medical Technology Policy)

Mr. Collette brings more than 3 decades of experience in the fields of Information Technology, Enterprise Security, Software Engineering, Infrastructure Design and Network Engineering to both mature operating companies and startups. He is also a recognized expert in the field of Cyber Security having authored two books on the subject, spoken domestically and internationally, and provided security consulting to Fortune 500 organizations and the Federal Government. The past 10 years has been focused in the area of Life Sciences and Biotech, applying best-practice and cutting-edge technology from the private sector and infusing it into the development of tools for personalized medicine as the CIO of both Clarient and Foundation Medicine Inc.

Mr. Collette brings to MED-C his years of expertise to build a world-class genomics and outcome database.

"Finding a cure for cancer requires harnessing the best efforts of patients, providers, pharmaceutical companies, laboratories, regulators, governments, academia and industry. MED-C is bringing together all these groups in such a way that everyone benefits. Our main project, a national next-generation sequencing and outcome registry will be ready to launch in the next 3 months, which we hope will provide advanced molecular testing to much of the nation with all information collected in a centralized, open-access database," said Dane J. Dickson, CEO of MED-C, "and Ron will make sure that it is built right."

"The singular focus of MED-C is advancing personalized medicine," comments Mr. Allen, "in connection with its commitment in an open-access research database, makes our effort unique. We believe Ron Collette will serve our organization and those that choose to join our membership well."

The board of directors of MED-C serves as non-paid volunteers for the work they do with MED-C. Given the extensive work that will be required in building the information technology outside of his board duties, Mr. Collette will receive a modest monthly consulting fee.

For further information, please contact MED-C at (208) 970-0244.

# # #